Urology · Salinas, CA
NPI
1235184912
Since 2006
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
559 Abbott St Ste A
Salinas, CA, 93901
Phone (831) 649-1000
Groups this clinician bills Medicare through
Medicare paid, 2024
$417K
23,184 services
Medicare patients, 2024
1,754
Average age 75
Drug cost, 2024
$855K
9,040 prescriptions
Company payments, 2025
$383
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Leonard G Renfer was code J1644 (injection, heparin sodium, per 1000 units), 6,087 times for 75 patients. In total Leonard G Renfer billed 23,184 services in 59 codes, and Medicare paid $417K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-07-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1644 Injection, heparin sodium, per 1000 units | Office | 6,087 | 75 | $0.18 | $1,084 |
| 99214 Office E&M - Established | Office | 1,879 | 1,453 | $90.40 | $170K |
| 81003 Clinical Chemistry | Office | 1,181 | 602 | $2.19 | $2,584 |
| 51700 Other Organ Systems | Office | 735 | 150 | $61.13 | $45K |
| 51798 Ultrasound - Nonspecific | Office | 610 | 574 | $8.88 | $5,419 |
| 99204 Office E&M - New | Office | 258 | 258 | $122.86 | $32K |
| 52000 Cystourethroscopy | Office | 185 | 170 | $198.81 | $37K |
| J0696 Injection, ceftriaxone sodium, per 250 mg | Office | 184 | 46 | $0.36 | $66.6 |
| 51702 Other Organ Systems | Office | 179 | 64 | $51.53 | $9,224 |
| 99213 Office E&M - Established | Office | 121 | 108 | $61.98 | $7,499 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 84 | 14 | $127.80 | $11K |
| 96372 Injection Administration | Office | 75 | 23 | $12.23 | $918 |
| 99214 Office E&M - Established | Facility | 67 | 62 | $74.89 | $5,018 |
| 76872 Ultrasound - Nonspecific | Office | 64 | 64 | $123.72 | $7,918 |
| 55700 Other Organ Systems | Office | 64 | 64 | $200.68 | $13K |
By year: 2022 $488K for 20,804 services; 2023 $392K for 15,807 services; 2024 $417K for 23,184 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,181 | 602 | $2.19 | $2,584 |
Medicare prescription drug claims, 2024
In 2024, the drug Leonard G Renfer prescribed most often to Medicare patients was Tamsulosin Hcl, with 2,909 prescriptions and refills. In total Leonard G Renfer wrote 9,040 Medicare prescriptions that cost $855K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 2,909 | 7,826 | 953 | $65K |
| Finasteride Generic | 2,240 | 6,144 | 742 | $40K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 931 | 2,521 | 353 | $35K |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 377 | 423 | 260 | $3,970 |
| Estradiol Generic | 357 | 659 | 160 | $23K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 247 | 263 | 135 | $1,327 |
| Trospium Chloride Generic | 215 | 578 | 92 | $9,416 |
| Myrbetriq Mirabegron | 213 | 519 | 69 | $231K |
| Alfuzosin Hcl Er Alfuzosin Hcl | 181 | 486 | 58 | $4,350 |
| Oxybutynin Chloride Generic | 159 | 412 | 53 | $3,914 |
| Doxazosin Mesylate Generic | 136 | 360 | 40 | $2,749 |
| Potassium Citrate Er Potassium Citrate | 88 | 214 | 26 | $9,168 |
| Ciprofloxacin Hcl Generic | 75 | 75 | 67 | $508 |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 71 | 75 | 37 | $1,292 |
| Tolterodine Tartrate Er Tolterodine Tartrate | 64 | 174 | 23 | $7,289 |
Brand drugs: - claims; generic drugs: 8,624 claims; opioid claims: 76.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Leonard G Renfer $383 ($383 in general payments such as food, travel and fees) from 8 companies. The largest payer was Janssen Biotech, Inc. with $141.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.